Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2083-2025

Brand Name: FEM-FLEX II Product Name: Femoral Arterial Cannula Recall

Brand Name: FEM-FLEX II Product Name: Femoral Arterial Cannula Model/Catalog Number: FEMII016AS Software Version: N/A Product Description: The Edwards FEMFLEXII Femoral Perfusion Cannluae provides or establishes arterial perfusion in the extracorporeal circuit for d 6 hours. Component: No

FDA recall Class I

Ongoing

FDA lists this Class I recall for Brand Name: FEM-FLEX II Product Name: Femoral Arterial Cannula. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2083-2025
Recall classification
Class I
Enforcement status
Ongoing
Initiation date
May 14, 2025
FDA report date
Jul 16, 2025
Quantity in commerce
847
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Brand Name: FEM-FLEX II Product Name: Femoral Arterial Cannula Model/Catalog Number: FEMII016AS Software Version: N/A Product Description: The Edwards FEMFLEXII Femoral Perfusion Cannluae provides or establishes arterial perfusion in the extracorporeal circuit for d 6 hours. Component: No

Affected model & UDI checker

Search the exact identifiers published for Z-2083-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
FEMII016ASBrand Name: FEM-FLEX II Product Name: Femoral Arterial CannulaCheck source noticeNot specified
Not specifiedBrand Name: FEM-FLEX II Product Name: Femoral Arterial CannulaCheck source notice0060913168341
FDA code information

Lot Code: Model No; FEMII016AS; UDI: 0060913168341; All lots up to: BSLC1689 Serial Numbers: FEMII016AS FEMII016AS FEMII016AS

View the original FDA recall notice

Why was this product recalled?

due to complaints received for 3mm to 4mm section wire exposed/protruding from the outside of the cannula body.

What actions did Edwards Lifesciences, LLC take?

On 05/16/2025, and 05/19/2025, the firm sent via FedEx overnight an "URGENT: PRODUCT RECALL" Letter to customers informing them that Edwards has confirmed a small number of occurrences impacting the OptiSite Arterial Perfusion cannula in which a 3mm to 4mm section of wire, from the wire-reinforcement coil at the cannula tip, was found to be released from the cannula body. The risk for the wire-reinforcement coil protruding out of the cannula body is major tissue damage and hemolysis. Customers are instructed to: " Verify their inventory on the attached customer acknowledgement form. " Share this notice with appropriate clinical staff at their site. " No patient follow-up or notification is necessary. " Return a completed Customer Acknowledgment Form to Edwards eCV Representative or via email to Edwards Customer Service at [email protected] within 15 days of receipt of this notification. " After receiving RGA number, return any impacted product to Edwards at the address below. A credit will be issued upon receipt of returned product. enableCV Distribution Center 6644 W. 2100 S. Suite D West Valley, UT 84128 For questions/assistance contact - Customer Service at 1-888-943-2783, or email: [email protected]

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology